ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 173 filers reported holding ACCELERON PHARMA INC in Q3 2018. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,442,000 | +623.1% | 20,000 | +300.0% | 0.05% | +487.5% |
| Q2 2020 | $476,000 | -94.0% | 5,000 | -96.7% | 0.01% | -95.5% |
| Q4 2019 | $7,953,000 | +11.8% | 150,000 | -16.7% | 0.18% | -9.7% |
| Q3 2019 | $7,112,000 | -13.4% | 180,000 | -10.0% | 0.20% | +4.3% |
| Q2 2019 | $8,216,000 | -4.6% | 200,000 | +8.1% | 0.19% | +69.4% |
| Q1 2019 | $8,615,000 | +19.9% | 185,000 | +12.1% | 0.11% | +15.6% |
| Q4 2018 | $7,186,000 | +4.6% | 165,000 | +37.5% | 0.10% | +12.9% |
| Q3 2018 | $6,868,000 | -5.6% | 120,000 | -20.0% | 0.08% | -16.7% |
| Q2 2018 | $7,278,000 | +3.4% | 150,000 | -16.7% | 0.10% | -30.1% |
| Q1 2018 | $7,038,000 | -7.9% | 180,000 | 0.0% | 0.15% | -11.0% |
| Q4 2017 | $7,639,000 | -3.7% | 180,000 | -15.3% | 0.16% | -16.8% |
| Q3 2017 | $7,931,000 | +117.5% | 212,500 | +77.1% | 0.20% | +169.9% |
| Q2 2017 | $3,647,000 | +236.1% | 120,000 | +192.7% | 0.07% | +386.7% |
| Q1 2017 | $1,085,000 | – | 41,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Artal Group S.A. | 1,400,000 | $133,378,000 | 3.73% |
| Foresite Capital Management III, LLC | 42,030 | $4,004,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 257,249 | $24,508,000 | 2.23% |
| Cormorant Asset Management, LP | 600,000 | $57,162,000 | 2.18% |
| Avoro Capital Advisors LLC | 1,040,000 | $99,081,000 | 1.96% |
| QVT Financial LP | 101,396 | $9,660,000 | 1.64% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,100,000 | $200,067,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 155,000 | $14,767,000 | 1.60% |
| Parkman Healthcare Partners LLC | 57,500 | $5,478,000 | 1.54% |
| Ikarian Capital, LLC | 187,700 | $17,882,000 | 1.42% |